Abhijit Khuranna’s Post

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

The era of clinical development is undergoing a transformation with the rise of AI and modern analytical tools. This has led to an emphasis on operational excellence and acceleration, as well as the ability to design more precise and efficient trials with greater success rates. By harnessing real world novel data and the power of AI, biopharmaceutical companies can move beyond Randomized Clinical Trials to vastly improve clinical development. At each stage of the development process, from formulating asset strategy to designing the protocol and trial planning, the benefits of AI and novel data sources accrue. For patients, this can lead to faster access to new treatments and more effective responses. This article from McKinsey highlights how RWD & AI can transform the landscape of Clinical development to accelerate drug discovery. https://lnkd.in/ghsvT6-w #AI #clinicaldevelopment #biopharmaceuticals #drugdiscovery

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Ben Green, MD, our SVP of Services, shares his insights with Pharmaceutical Executive on how pharma and remote patient monitoring companies can work together to make decentralized clinical trials more commonly available. Read more below. #ClinicalTrials #ClinicalResearch #RPM #Pharma #DCT

📰 Drug discovery is a particularly time-consuming process. The pre-clinical stage alone can take three to six years. Open-source tools can be invaluable in accelerating clinical trial timelines by fast-tracking new therapies ⬇️ https://lnkd.in/eNvu9ahc

To retain its status as the world's premier biotech hub, Boston's pharmaceutical companies must adapt to the opportunities and complexities brought by advanced therapies and personalized medicine. Kostja and I discuss the changes companies must consider and how they can stay on top for Boston Business Journal. Read here! https://lnkd.in/ewnqjbVi

I found this article very interesting, especially the way it highlights the impact of technology on healthcare and its potential to influence the future of the pharmaceutical industry. I would therefore like to share a summary highlighting the key points and implications of this technological evolution. The decentralisation of clinical trials, supported by remote patient monitoring (RPM) technologies, marks a fundamental shift in pharmaceutical research. This approach not only broadens inclusion, allowing individuals from diverse locations and backgrounds to participate without the challenges of travel to specialised centres, but also optimises resources by reducing reliance on costly physical infrastructure. In addition, decentralised clinical trials (DCT) with RPM support significantly improve the patient experience by enabling continuous, real-time monitoring of side effects and treatment efficacy in the patient's everyday environment. This not only improves the accuracy of the data collected, but also accelerates drug development and increases the return on investment for pharmaceutical companies. I sincerely welcome the sharing of this kind of information, which not only illustrates current progress but also inspires future improvements in the field of health and technology.

Final round of my personal insights from our report “2024 Global Life Sciences Sector Outlook”. 🔗 Full report here: https://lnkd.in/dJS-WPAN 💊 Drug Development: Collaboration, CDMS’s Booming and Transforming into CRDMOs 📈 There is a proliferation of collaborative research agreements/partnerships in the early drug discovery and preclinical drug development stages. In clinical trials, patient recruitment and clinical lab and diagnostics testing areas are seeing more outsourcing. The number of contract research organizations (CROs) is growing. 💼 M&A deal value across CROs/CDMOs/suppliers has jumped nearly 85% year over year to US$28.3 billion, while volume is up 50%. CDMOs are expected to attract more PE interest in 2024 and beyond as the need for highly specialized manufacturing facilities continues to increase. 🚀 Drug makers are starting to seek out contract research development manufacturing organizations (CRDMOs). These operators consider themselves science and technology platforms that also bring the “R,” or research, into the CDMO mix. CRDMO facilities are starting to spring up around the world—including in China, Singapore, the US, and Italy. 🌍 While some pharma companies in Europe favor regional CDMO services for close proximity to markets, innovation capabilities, and talent, CDMO services are being globalized by China and India. 🤝 Shared Decisions with Patients and Biomarkers Development Result in More Diagnostics and DTC Testing 💡 There is an opportunity to increase awareness about the role of shared decision-making (SDM), and evidence shows that SDM can promote appropriate care, decrease overtreatment, improve health outcomes, and thereby, may reduce health care costs. 🌱 Up to 80% of health outcomes can be driven by nonclinical factors, such as access to transportation, education, job opportunities, nutritious food, and safe housing. 🔄 As some patients strive for more autonomy, life sciences companies are exploring new channels and partners to engage directly with patients rather than relying solely on HCPs. More direct-to-consumer (DTC) health services are launching to address patient concerns and preferences more expeditiously. As these services become more prevalent, effective, safe, and cost-effective, they’re likely to grow in popularity. 📊 The DTC lab testing market is projected to reach a hefty US$1.59 billion by 2030, signifying a paradigm shift in health care dynamics due to personalized diagnostics. 🧬 The biomarker space right now is advancing rapidly. 📈 Megatrends – Longevity 🌟 A paradigm shift is underway—from disease-focused treatments to those that address the underlying mechanisms of aging, biological systems, and wellness. The goal is to extend health span, not just life span. 🎗️ Cancer is starting to affect more adults younger than 50 years of age, with an 80% rise in the cancer rate from three decades ago.